Immune-mediated Colitis from Dual Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Immunotherapy has revolutionized advanced melanoma treatment, improving patient survival rates.
• Despite efficacy, immune-related adverse events (irAEs) are a significant concern with these novel therapies.
• Checkpoint inhibitors, a class of immunotherapy agents, modulate the immune system to fight cancer.

Observation:

• A 53-year-old woman presented with two weeks of severe diarrhea following treatment with dual immunotherapy agents for advanced melanoma.
• Diagnostic workup confirmed pancolitis, strongly suspected to be an adverse effect of the immunotherapy.
• Initial conservative management failed to alleviate the patient's symptoms.

Findings:

• The patient's pancolitis, a severe gastrointestinal irAE, did not improve with conservative measures.
• Introduction of corticosteroid therapy led to clinical improvement, indicating an immune-mediated inflammatory process.

Implications:

• This case highlights the potential for severe immune-mediated toxicities, such as pancolitis, associated with dual immunotherapy in melanoma.
• Physicians must remain vigilant for irAEs, including gastrointestinal manifestations, when managing patients on checkpoint inhibitors.
• Prompt recognition and appropriate management, including the use of steroids, are crucial for addressing these immunotherapy-induced toxicities.